These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17530007

  • 1. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
    Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC.
    Bone Marrow Transplant; 2007 Jul; 40(2):137-43. PubMed ID: 17530007
    [Abstract] [Full Text] [Related]

  • 2. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E, Haun M, Grünewald K, Gastl G.
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [Abstract] [Full Text] [Related]

  • 3. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
    Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK, Oertel J, Nitsche A, Siegert W.
    Bone Marrow Transplant; 2003 Oct; 32(7):695-701. PubMed ID: 13130317
    [Abstract] [Full Text] [Related]

  • 5. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
    Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P.
    Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
    [Abstract] [Full Text] [Related]

  • 6. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.
    Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D, Sainty D, Gastaut JA, Viens P, Olive D, Gaugler B.
    Bone Marrow Transplant; 2004 Apr; 33(8):839-46. PubMed ID: 14767500
    [Abstract] [Full Text] [Related]

  • 8. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
    Kalpoe JS, van der Heiden PL, Barge RM, Houtzager S, Lankester AC, van Tol MJ, Kroes AC.
    Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B, Kerridge I, Gilroy N, Huang G, Hertzberg M, Gottlieb D, Bradstock K.
    Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N.
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [Abstract] [Full Text] [Related]

  • 11. Clinical aspects of CMV infection after stem cell transplantation.
    Hebart H, Einsele H.
    Hum Immunol; 2004 May; 65(5):432-6. PubMed ID: 15172442
    [Abstract] [Full Text] [Related]

  • 12. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.
    Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D, Arnoulet C, Chabannon C, Vey N, Camerlo J, Bouabdallah R, Maraninchi D, Bardou VJ, Blaise D.
    Transfusion; 2004 Apr; 44(4):501-8. PubMed ID: 15043564
    [Abstract] [Full Text] [Related]

  • 13. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
    Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV.
    Bone Marrow Transplant; 2007 Jul; 40(2):125-36. PubMed ID: 17530009
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
    Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U.
    Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
    [Abstract] [Full Text] [Related]

  • 15. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
    Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ.
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
    [Abstract] [Full Text] [Related]

  • 16. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA.
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [Abstract] [Full Text] [Related]

  • 17. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation.
    Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D, Arnoulet C, Chabannon C, Vey N, Camerlo J, Bouabdallah R, Viens P, Maraninchi D, Bardou VJ, Esterni B, Blaise D.
    Bone Marrow Transplant; 2005 Nov; 36(10):901-6. PubMed ID: 16151421
    [Abstract] [Full Text] [Related]

  • 18. An assessment of the effect of human herpesvirus-6 replication on active cytomegalovirus infection after allogeneic stem cell transplantation.
    Tormo N, Solano C, de la Cámara R, Garcia-Noblejas A, Cardeñoso L, Clari MA, Nieto J, López J, Hernández-Boluda JC, Remigia MJ, Benet I, Navarro D.
    Biol Blood Marrow Transplant; 2010 May; 16(5):653-61. PubMed ID: 20005968
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure.
    Subirà M, Sureda A, Ancín I, Martino R, Altés A, Brunet S, Sierra J.
    Bone Marrow Transplant; 2003 Nov; 32(9):869-72. PubMed ID: 14561986
    [Abstract] [Full Text] [Related]

  • 20. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.